Importantly, the combination of the CD38 antibody and CD20-directed bibodies [CD20×NKG2D#3] or [CD20×NKG2D#32] was, with 33.0% and 45.2%, significantly more effective in triggering effector cell killing of tumor cells than the single agents. The gene discussed is CD38; the disease is neoplasm.